tiprankstipranks
Advertisement
Advertisement

Albertsons Announces Opioid Settlement Framework and Outlook

Story Highlights
  • Albertsons agreed to a $774 million opioid settlement framework, recorded a large charge, and plans nine-year payments starting April 2026.
  • Despite the opioid charge, Albertsons posted solid adjusted results, raised its dividend, expanded buybacks, refinanced debt, and issued a steady 2026 outlook.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Albertsons Announces Opioid Settlement Framework and Outlook

Claim 55% Off TipRanks

Albertsons Companies ( (ACI) ) just unveiled an announcement.

On April 14, 2026, Albertsons unveiled a settlement framework to resolve substantially all opioid-related claims from participating states, local governments and Native American tribes, agreeing to pay about $774 million over nine years, with the first payment expected on April 30, 2026, and recording a related $774 million pre-tax charge in its fiscal 2025 fourth quarter results. The company also reported modest identical sales growth and strong digital gains for fiscal 2025, raised its quarterly dividend by 13% to $0.17 per share, expanded its remaining share repurchase authorization to $2 billion, refinanced debt with new longer-dated notes, and issued a fiscal 2026 outlook that targets steady earnings and cash flow to support continued capital returns and investment.

For the fourth quarter of fiscal 2025, Albertsons posted a net loss of $480.8 million driven by the opioid charge, while adjusted net income reached $251.7 million and Adjusted EBITDA rose to $903.4 million, aided by an extra week and ongoing productivity efforts. For the full fiscal year, it generated $217 million in net income, $1.21 billion in adjusted net income, and $3.9 billion in Adjusted EBITDA, while investing heavily in remodels, new stores, and technology and anticipating fiscal 2026 identical sales growth of up to 1% alongside capital expenditures of roughly $2 billion.

The most recent analyst rating on (ACI) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Albertsons Companies stock, see the ACI Stock Forecast page.

Spark’s Take on ACI Stock

According to Spark, TipRanks’ AI Analyst, ACI is a Neutral.

The score is held back primarily by high leverage and thinner recent profitability despite solid cash generation. Offsetting factors include a reasonable valuation with a supportive dividend, generally steady/neutral technicals, and an earnings update that emphasized continued growth initiatives and productivity progress while acknowledging meaningful near-term headwinds.

To see Spark’s full report on ACI stock, click here.

More about Albertsons Companies

Albertsons Companies, Inc., based in Boise, Idaho, operates as a major U.S. food and drug retailer under the NYSE ticker ACI, running supermarket banners with significant in-store pharmacy operations and a growing digital and loyalty platform. The company focuses on expanding e‑commerce, enhancing its customer value proposition, and driving long‑term shareholder returns through dividends and share repurchases.

Average Trading Volume: 6,425,310

Technical Sentiment Signal: Sell

Current Market Cap: $8.88B

Learn more about ACI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1